Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Completed 1Active not recruiting 1

Sponsor Class

NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Plasma cell 1Myeloid 1Lymphoid 1

Conditions

Prostatic Neoplasms 22Breast Neoplasms 21Neoplasms 10Brain Neoplasms 10Glioma 8Head and Neck Neoplasms 7Lymphoma 6Colonic Neoplasms 6Urinary Bladder Neoplasms 5Rectal Neoplasms 5Pancreatic Neoplasms 5Lymphoma, Non-Hodgkin 5Uterine Cervical Neoplasms 4Triple Negative Breast Neoplasms 4Glioblastoma 4Carcinoma, Hepatocellular 4Astrocytoma 4Squamous Cell Carcinoma of Head and Neck 3Spinal Cord Neoplasms 3Lung Neoplasms 3Stomach Neoplasms 2Sarcoma 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Oligodendroglioma 2Neurofibromatosis 1 2Neoplasm Metastasis 2Multiple Myeloma 2Meningioma 2Lymphoma, B-Cell 2Liver Neoplasms 2

Interventions

Cyclophosphamide 344Cytarabine 281fludarabine phosphate 201Methotrexate 185Filgrastim 159Busulfan 147Etoposide 135Peripheral Blood Stem Cell Transplantation 133fludarabine 127Rituximab 119Radiotherapy 111Vincristine 102Cyclosporine 98Daunorubicin 96Antilymphocyte Serum 94Dexamethasone 91Tacrolimus 85Mycophenolic Acid 85Whole-Body Irradiation 80Melphalan 79Idarubicin 67Imatinib Mesylate 66Mercaptopurine 65Granulocyte Colony-Stimulating Factor 65Azacitidine 65Methylprednisolone 59Doxorubicin 58Prednisone 57Clofarabine 54sargramostim 53

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Leukemia × Magnetic Resonance Imaging × Clear all
NCT02356159 2025-09-30

Study of Palifermin (Kepivance) in Persons Undergoing Unrelated Donor Allogeneic Hematopoietic Cell Transplantation

National Institutes of Health Clinical Center (CC)

Phase 1/2 Completed
34 enrolled 18 charts
LymphoidMyeloidOther hematologic neoplasmPlasma cell

Hodgkin Disease, Leukemia, Lymphoma, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes

NCT00923013 2025-08-08

Cladribine With Simultaneous or Delayed Rituximab to Treat Hairy Cell Leukemia

National Institutes of Health Clinical Center (CC)

Phase 2 Active not recruiting
175 enrolled 16 charts
Other hematologic neoplasm

Leukemia, Leukemia, Hairy Cell, Neoplasm, Residual

Data powered by HemOnc (CC BY 4.0) Colophon âš¡